Previous studies have demonstrated that higher TYMS expression is associated with a lower chemotherapeutic effect of pemetrexed in patients with a variety of solid tumors [54]–[56] and forced overexpression of TYMS in NSCLC cells reduced sensitivity to pemetrexed [57]. This evidence concerns the gene TYMS and non-small cell lung carcinoma.